Saturday 17 October 2026
Export MDWD’s income statement to Excel — free account
MediWound Ltd.
MDWD Healthcare Biotechnology
MediWound Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17.0 million, down 16.1% from fiscal 2024. In the quarter to June 2026, revenue fell 45.8%, EPS grew 53.7%, free cash flow fell 49.9% and total debt rose 51.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
11.85
0.36
−2.95%
Follow MDWD
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
9.49 | 12.38 | 14.32 | 15.97 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(61.32) | (69.64) | (30.71) | (20.75) | |
P/B ratio |
9.87 | 4.81 | 4.75 | 5.31 | |
Price to Tangible BV |
9.90 | 4.82 | 4.76 | 5.32 | |
EV/Sales |
6.72 | 9.30 | 11.30 | 13.06 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(9.54) | (9.79) | (8.72) | (7.00) | |
EV/FCF |
(7.54) | (7.28) | (6.50) | (5.42) | |
Quick Ratio |
2.48 | 2.17 | 2.19 | 2.09 | |
Current Ratio |
2.65 | 2.33 | 2.41 | 2.32 | |
Net Debt/EBITDA |
9.50 | 7.35 | 5.75 | 3.90 | |
Debt/Assets |
1.12% | 1.01% | 1.16% | 0.00% | |
Debt/Equity |
0.02 | 0.02 | 0.02 | 0.00 | |
Asset Turnover |
0.25 | 0.21 | 0.19 | 0.17 | |
Operating CF/Net income |
1.22 | 0.42 | 2.29 | 1.23 | |
Capex/Depreciation |
(2.50) | (3.55) | (4.81) | (2.67) | |
Interest Coverage |
— | 1.41 | — | (8.44) | |
Research and Development Expense of Revenue |
63.82% | 239.85% | 351.53% | 190.85% | |
Selling, General and Administrative Expense of Revenue |
72.87% | 193.73% | 241.15% | 125.94% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
13.63% | 35.46% | 43.66% | 24.42% | |
Graham Net Nets |
0.13 | 0.08 | 0.07 | 0.04 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(10.54%) | (11.38%) | (14.03%) | (10.88%) | |
Free Cash Flow Yield |
(9.39%) | (10.32%) | (12.14%) | (15.08%) | |
Revenue per Share |
0.49 | 0.16 | 0.11 | 0.24 | |
Operating CF per Share |
(0.29) | (0.27) | (0.52) | (0.71) | |
Capex per Share |
(0.09) | (0.22) | (0.14) | (0.08) | |
Free Cash Flow per Share |
(0.39) | (0.48) | (0.67) | (0.79) | |
Cash per Share |
5.36 | 4.67 | 3.47 | 2.74 | |
Shareholders Equity per Share |
4.55 | 3.84 | 3.22 | 2.77 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.55 | 3.84 | 3.22 | 2.77 | |
Free Cash Flow |
(4.28) | (5.47) | (8.57) | (10.20) | |
Working Capital |
43.28 | 34.26 | 30.52 | 24.41 | |
Capital Expenditures |
(1.04) | (2.45) | (1.82) | (1.07) | |
Net Current Asset Value |
25.27 | 17.34 | 13.61 | 6.72 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.19 | 1.31 | 1.23 | 0.35 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
5.67 | 4.52 | 3.96 | 5.15 | |
Average Payables |
5.82 | 6.46 | 6.20 | 6.75 | |
Average Inventory |
3.71 | 3.39 | 4.18 | 3.98 | |
Average Assets |
84.58 | 79.88 | 74.50 | 69.44 | |
Average Common Equity |
— | 37.61 | — | 26.76 |
Columns are period end dates